SCHEMBL5841158

SCHEMBL5841158

COC(=O)c1cc(Sc2ccc(C)c(-c3ccccc3)c2)c([N+](=O)[O-])s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 1/20 0.40
SELE P16581 1/20 0.40
VCAM1 P19320 1/20 0.40
ALDH1A1 P00352 7/20 0.36
HPGD P15428 4/20 0.36
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
PRKCZ Q05513 1/20 0.35
USP47 Q96K76 1/20 0.35
MAPT P10636 4/20 0.35
GAA P10253 1/20 0.35
OPRD1 P41143 1/20 0.34
HTT P42858 2/20 0.34
POLB P06746 2/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
KDM4E B2RXH2 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5839296 0.84 ALDH1A1 (0.43) ICAM1SELEVCAM1ALDH1A1HPGD
SCHEMBL5840567 0.79 XDH (0.41) ICAM1SELEVCAM1ALDH1A1HPGD
SCHEMBL5840329 0.78 PTGS2 (0.39) VCAM1ALDH1A1HPGDLMNAKMT2A
SCHEMBL5841470 0.78 ICAM1 (0.39) ICAM1SELEVCAM1ALDH1A1HPGD
SCHEMBL5840563 0.78 EDNRA (0.43) ICAM1SELEVCAM1ALDH1A1KMT2A
SCHEMBL5840639 0.75 MAPT (0.41) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL27612076 0.72 ALDH1A1 (0.35) VCAM1ALDH1A1HPGDLMNAKMT2A
SCHEMBL5841241 0.72 ICAM1 (0.41) ICAM1SELEVCAM1ALDH1A1HPGD
SCHEMBL8363261 0.70 USP10 (0.42) VCAM1ALDH1A1HPGDLMNAKMT2A
SCHEMBL5841225 0.70 ICAM1 (0.43) ICAM1SELEVCAM1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ICAM1 3438/4885SELE 181/4885VCAM1 3273/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ICAM1 3387/4885SELE 331/4885VCAM1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.